The Experts below are selected from a list of 3120 Experts worldwide ranked by ideXlab platform
Drew A Hall - One of the best experts on this subject based on the ideXlab platform.
-
dataset on optimization and development of a point of care Glucometer based sars cov 2 detection assay using aptamers
2021Co-Authors: Naveen K Singh, Partha Ray, Aaron F Carlin, Celestine Magallanes, Sydney C Morgan, Louise C Laurent, Eliah Aronoffspencer, Drew A HallAbstract:We present supplementary data for the published article, "Hitting the diagnostic sweet spot: Point-of-care SARS-CoV-2 salivary antigen testing with an off-the-shelf Glucometer" [1]. The assay described is designed to be performed at home or in a clinic without expensive instrumentation or professional training. SARS-CoV-2 is detected by an aptamer-based assay that targets the Nucleocapsid (N) or Spike (S) antigens. Binding of the N or S protein to their respective aptamer results in the competitive release of a complementary antisense-invertase enzyme complex. The released enzyme then catalyzes the conversion of sucrose to glucose that is measured by an off-the-shelf Glucometer. The data presented here describe the optimization of the assay parameters and their contribution to developing this aptamer-based assay to detect SARS-CoV-2. The assay performance was checked in a standard buffer, contrived samples, and patient samples validated with well-established scientific methods. The resulting dataset can be used to further develop Glucometer-based assays for diagnosing other communicable and non-communicable diseases.
-
hitting the diagnostic sweet spot point of care sars cov 2 salivary antigen testing with an off the shelf Glucometer
2021Co-Authors: Naveen K Singh, Partha Ray, Aaron F Carlin, Celestine Magallanes, Sydney C Morgan, Louise C Laurent, Eliah Aronoffspencer, Drew A HallAbstract:Significant barriers to the diagnosis of latent and acute SARS-CoV-2 infection continue to hamper population-based screening efforts required to contain the COVID-19 pandemic in the absence of widely available antiviral therapeutics or vaccines. We report an aptamer-based SARS-CoV-2 salivary antigen assay employing only low-cost reagents ($3.20/test) and an off-the-shelf Glucometer. The test was engineered around a Glucometer as it is quantitative, easy to use, and the most prevalent piece of diagnostic equipment globally, making the test highly scalable with an infrastructure that is already in place. Furthermore, many Glucometers connect to smartphones, providing an opportunity to integrate with contact tracing apps, medical providers, and electronic health records. In clinical testing, the developed assay detected SARS-CoV-2 infection in patient saliva across a range of viral loads - as benchmarked by RT-qPCR - within 1 h, with 100% sensitivity (positive percent agreement) and distinguished infected specimens from off-target antigens in uninfected controls with 100% specificity (negative percent agreement). We propose that this approach provides an inexpensive, rapid, and accurate diagnostic for distributed screening of SARS-CoV-2 infection at scale.
-
hitting the diagnostic sweet spot point of care sars cov 2 salivary antigen testing with an off the shelf Glucometer
2020Co-Authors: Naveen K Singh, Partha Ray, Aaron F Carlin, Celestine Magallanes, Sydney C Morgan, Louise C Laurent, Eliah Aronoffspencer, Drew A HallAbstract:Abstract Significant barriers to the diagnosis of latent and acute SARS-CoV-2 infection continue to hamper population-based screening efforts required to contain the COVID-19 pandemic in the absence of effective antiviral therapeutics or vaccines. We report an aptamer-based SARS-CoV-2 salivary antigen assay employing only low-cost reagents ($3.20/test) and an off-the-shelf Glucometer. The test was engineered around a Glucometer as it is quantitative, easy to use, and the most prevalent piece of diagnostic equipment globally making the test highly scalable with an infrastructure that is already in place. Furthermore, many Glucometers connect to smartphones providing an opportunity to integrate with contract tracing apps, medical providers, and electronic medical records. In clinical testing, the developed assay detected SARS-CoV-2 infection in patient saliva across a range of viral loads - as benchmarked by RT-qPCR - within one hour, with 100% sensitivity (positive percent agreement) and distinguished infected specimens from off-target antigens in uninfected controls with 100% specificity (negative percent agreement). We propose that this approach can provide an inexpensive, rapid, and accurate diagnostic for distributed screening of SARS-CoV-2 infection at scale.
Dianping Tang - One of the best experts on this subject based on the ideXlab platform.
-
Graphene oxide-gated mesoporous silica nanocontainers using aptamers for arsenite detection with Glucometer readout
2018Co-Authors: Qian Zhou, Dianping TangAbstract:A newly portable detection sensing platform based on a graphene oxide (GO)-gated mesoporous silica nanocontainer (MSN) was designed for arsenite detection through the target-responsive release of glucose from the MSN with a Glucometer readout. To construct such a biosensing system, the arsenite aptamer was initially conjugated covalently onto the mesoporous silica nanoparticles through the epoxy-amino reaction. Thereafter, the indicators (glucose molecules) were gated into the pores by using graphene oxide nanosheets, on the basis of π-stacking interactions between the nucleobases and graphene. Upon target arsenite introduction, graphene oxide was displaced from the MSN thanks to a specific reaction between the analyte and the aptamer, thus resulting in the opening of the pores to release the loaded glucose molecules, which could be determined quantitatively by using a portable personal Glucometer (PGM). Based on the different affinities between graphene and the analyte for the labeled aptamer on the MSN, the amount of released glucose molecules from the pores increased with the increasing arsentite concentrations. Under optimal conditions, the GO-gated aptasensing system exhibited good PGM responses relative to arsenite concentrations within the dynamic working range of 0.01–100 ng mL−1 (ppb) at a detection limit of 2.3 pg mL−1 (ppt). The coefficients of variation (CVs) for the reproducibility of intra-assay and inter-assay were below 9.1% and 11.6%, respectively. In addition, the methodology also displayed high specificity and selectivity towards target arsenite against other ions, and was applicable for monitoring arsenite in water samples, giving well-matched results in accordance with the referenced ICP-MS.
-
invertase labeling gold dendrimer for in situ amplified detection mercury ii with Glucometer readout and thymine hg 2 thymine coordination chemistry
2016Co-Authors: Zhenli Qiu, Jian Shu, Guixiao Jin, Qiaohua Wei, Guonan Chen, Dianping TangAbstract:A simple, low-cost transducer with Glucometer readout was designed for sensitive detection of mercury(II) (Hg(2+)), coupling with thymine-Hg(2+)-thymine (T-Hg(2+)-T) coordination chemistry and invertase-functionalized gold-dendrimer nanospheres for the signal amplification. Initially, nanogold-encapsulated poly(amidoamine) dendrimers (Au DENs) were synthesized by in-situ reduction of gold(III). Thereafter, the as-prepared Au DENs were utilized for the labeling of invertase and T-rich signal DNA probe. In the presence of target Hg(2+), the functionalized Au DENs were conjugated to capture DNA probe-modified electrode via T-Hg(2+)-T coordination chemistry. Accompanying the Au DENs, the labeled invertase could hydrolyze sucrose into glucose, which could be quantitatively monitored by an external personal Glucometer (PGM). The PGM signal increased with the increasing target Hg(2+) in the sample. Under the optimal conditions, our designed sensing platform exhibited good PGM responses toward target Hg(2+), and allowed the detection of Hg(2+) at a concentration as low as 4.2 pM. This sensing system also displayed remarkable specificity relative to target Hg(2+) against other competing ions, and could be applied for reliable monitoring of spiked Hg(2+) into the environmental water samples with satisfactory results. With the advantages of cost-effectiveness, simplicity, portability, and convenience, our strategy provides a tremendous potential to be a promising candidate for point-of-use monitoring of non-glucose targets by the public.
-
bioresponsive controlled release from mesoporous silica nanocontainers with Glucometer readout
2014Co-Authors: Li Hou, Guonan Chen, Chunling Zhu, Dianping TangAbstract:A novel sensing platform for monitoring small molecules without the need for sample separation and washing is developed by using a commercialized personal glucose meter based on bioresponsive controlled release of glucose from aptamer-gated mesoporous silica nanocontainers.
Naveen K Singh - One of the best experts on this subject based on the ideXlab platform.
-
dataset on optimization and development of a point of care Glucometer based sars cov 2 detection assay using aptamers
2021Co-Authors: Naveen K Singh, Partha Ray, Aaron F Carlin, Celestine Magallanes, Sydney C Morgan, Louise C Laurent, Eliah Aronoffspencer, Drew A HallAbstract:We present supplementary data for the published article, "Hitting the diagnostic sweet spot: Point-of-care SARS-CoV-2 salivary antigen testing with an off-the-shelf Glucometer" [1]. The assay described is designed to be performed at home or in a clinic without expensive instrumentation or professional training. SARS-CoV-2 is detected by an aptamer-based assay that targets the Nucleocapsid (N) or Spike (S) antigens. Binding of the N or S protein to their respective aptamer results in the competitive release of a complementary antisense-invertase enzyme complex. The released enzyme then catalyzes the conversion of sucrose to glucose that is measured by an off-the-shelf Glucometer. The data presented here describe the optimization of the assay parameters and their contribution to developing this aptamer-based assay to detect SARS-CoV-2. The assay performance was checked in a standard buffer, contrived samples, and patient samples validated with well-established scientific methods. The resulting dataset can be used to further develop Glucometer-based assays for diagnosing other communicable and non-communicable diseases.
-
hitting the diagnostic sweet spot point of care sars cov 2 salivary antigen testing with an off the shelf Glucometer
2021Co-Authors: Naveen K Singh, Partha Ray, Aaron F Carlin, Celestine Magallanes, Sydney C Morgan, Louise C Laurent, Eliah Aronoffspencer, Drew A HallAbstract:Significant barriers to the diagnosis of latent and acute SARS-CoV-2 infection continue to hamper population-based screening efforts required to contain the COVID-19 pandemic in the absence of widely available antiviral therapeutics or vaccines. We report an aptamer-based SARS-CoV-2 salivary antigen assay employing only low-cost reagents ($3.20/test) and an off-the-shelf Glucometer. The test was engineered around a Glucometer as it is quantitative, easy to use, and the most prevalent piece of diagnostic equipment globally, making the test highly scalable with an infrastructure that is already in place. Furthermore, many Glucometers connect to smartphones, providing an opportunity to integrate with contact tracing apps, medical providers, and electronic health records. In clinical testing, the developed assay detected SARS-CoV-2 infection in patient saliva across a range of viral loads - as benchmarked by RT-qPCR - within 1 h, with 100% sensitivity (positive percent agreement) and distinguished infected specimens from off-target antigens in uninfected controls with 100% specificity (negative percent agreement). We propose that this approach provides an inexpensive, rapid, and accurate diagnostic for distributed screening of SARS-CoV-2 infection at scale.
-
hitting the diagnostic sweet spot point of care sars cov 2 salivary antigen testing with an off the shelf Glucometer
2020Co-Authors: Naveen K Singh, Partha Ray, Aaron F Carlin, Celestine Magallanes, Sydney C Morgan, Louise C Laurent, Eliah Aronoffspencer, Drew A HallAbstract:Abstract Significant barriers to the diagnosis of latent and acute SARS-CoV-2 infection continue to hamper population-based screening efforts required to contain the COVID-19 pandemic in the absence of effective antiviral therapeutics or vaccines. We report an aptamer-based SARS-CoV-2 salivary antigen assay employing only low-cost reagents ($3.20/test) and an off-the-shelf Glucometer. The test was engineered around a Glucometer as it is quantitative, easy to use, and the most prevalent piece of diagnostic equipment globally making the test highly scalable with an infrastructure that is already in place. Furthermore, many Glucometers connect to smartphones providing an opportunity to integrate with contract tracing apps, medical providers, and electronic medical records. In clinical testing, the developed assay detected SARS-CoV-2 infection in patient saliva across a range of viral loads - as benchmarked by RT-qPCR - within one hour, with 100% sensitivity (positive percent agreement) and distinguished infected specimens from off-target antigens in uninfected controls with 100% specificity (negative percent agreement). We propose that this approach can provide an inexpensive, rapid, and accurate diagnostic for distributed screening of SARS-CoV-2 infection at scale.
George M Whitesides - One of the best experts on this subject based on the ideXlab platform.
-
a paper based pop up electrochemical device for analysis of beta hydroxybutyrate
2016Co-Authors: Chienchung Wang, Jonathan W Hennek, Alar Ainla, Ashok A Kumar, Wenjie Lan, Barbara S Smith, Mengxia Zhao, George M WhitesidesAbstract:This paper describes the design and fabrication of a "pop-up" electrochemical paper-based analytical device (pop-up-EPAD) to measure beta-hydroxybutyrate (BHB)-a biomarker for diabetic ketoacidosis-using a commercial combination BHB/Glucometer. Pop-up-EPADs are inspired by pop-up greeting cards and children's books. They are made from a single sheet of paper folded into a three-dimensional (3D) device that changes shape, and fluidic and electrical connectivity, by simply folding and unfolding the structure. The reconfigurable 3D structure makes it possible to change the fluidic path and to control timing; it also provides mechanical support for the folded and unfolded structures that enables good registration and repeatability on folding. A pop-up-EPAD designed to detect BHB shows performance comparable to commercially available plastic test strips over the clinically relevant range of BHB in blood when used with a commercial Glucometer that integrates the ability to measure glucose and BHB (combination BHB/Glucometer). With simple modifications of the electrode and the design of the fluidic path, the pop-up-EPAD also detects BHB in buffer using a simple Glucometer-a device that is more available than the combination BHB/Glucometer. Strategies that use a "3D pop-up"-that is, large-scale changes in 3D structure and fluidic paths-by folding/unfolding add functionality to EPADs (e.g., controlled timing, fluidic handling and path programming, control over complex sequences of steps, and alterations in electrical connectivity) and should enable the development of new classes of paper-based diagnostic devices.
-
a paper based pop up electrochemical device for analysis of beta hydroxybutyrate
2016Co-Authors: Chienchung Wang, Jonathan W Hennek, Alar Ainla, Barbara S Smith, Mengxia Zhao, Ashok Kumar, Judy S Im, George M WhitesidesAbstract:This paper describes the design and fabrication of a “pop-up” electrochemical paper-based analytical device (pop-up-EPAD) to measure beta-hydroxybutyrate (BHB)—a biomarker for diabetic ketoacidosis—using a commercial combination BHB/Glucometer. Pop-up-EPADs are inspired by pop-up greeting cards and children’s books. They are made from a single sheet of paper folded into a three-dimensional (3D) device that changes shape, and fluidic and electrical connectivity, by simply folding and unfolding the structure. The reconfigurable 3D structure makes it possible to change the fluidic path and to control timing; it also provides mechanical support for the folded and unfolded structures that enables good registration and repeatability on folding. A pop-up-EPAD designed to detect BHB shows performance comparable to commercially available plastic test strips over the clinically relevant range of BHB in blood when used with a commercial Glucometer that integrates the ability to measure glucose and BHB (combination B...
-
integration of paper based microfluidic devices with commercial electrochemical readers
2010Co-Authors: Zhihong Nie, Frederique Deiss, Xinyu Liu, Ozge Akbulut, George M WhitesidesAbstract:The combination of simple Electrochemical Micro-Paper-based Analytical Devices (EµPADs) with commercially available Glucometers allows rapid, quantitative electrochemical analysis of a number of compounds relevant to human health (e.g., glucose, cholesterol, lactate, and alcohol) in blood or urine.
Aaron F Carlin - One of the best experts on this subject based on the ideXlab platform.
-
dataset on optimization and development of a point of care Glucometer based sars cov 2 detection assay using aptamers
2021Co-Authors: Naveen K Singh, Partha Ray, Aaron F Carlin, Celestine Magallanes, Sydney C Morgan, Louise C Laurent, Eliah Aronoffspencer, Drew A HallAbstract:We present supplementary data for the published article, "Hitting the diagnostic sweet spot: Point-of-care SARS-CoV-2 salivary antigen testing with an off-the-shelf Glucometer" [1]. The assay described is designed to be performed at home or in a clinic without expensive instrumentation or professional training. SARS-CoV-2 is detected by an aptamer-based assay that targets the Nucleocapsid (N) or Spike (S) antigens. Binding of the N or S protein to their respective aptamer results in the competitive release of a complementary antisense-invertase enzyme complex. The released enzyme then catalyzes the conversion of sucrose to glucose that is measured by an off-the-shelf Glucometer. The data presented here describe the optimization of the assay parameters and their contribution to developing this aptamer-based assay to detect SARS-CoV-2. The assay performance was checked in a standard buffer, contrived samples, and patient samples validated with well-established scientific methods. The resulting dataset can be used to further develop Glucometer-based assays for diagnosing other communicable and non-communicable diseases.
-
hitting the diagnostic sweet spot point of care sars cov 2 salivary antigen testing with an off the shelf Glucometer
2021Co-Authors: Naveen K Singh, Partha Ray, Aaron F Carlin, Celestine Magallanes, Sydney C Morgan, Louise C Laurent, Eliah Aronoffspencer, Drew A HallAbstract:Significant barriers to the diagnosis of latent and acute SARS-CoV-2 infection continue to hamper population-based screening efforts required to contain the COVID-19 pandemic in the absence of widely available antiviral therapeutics or vaccines. We report an aptamer-based SARS-CoV-2 salivary antigen assay employing only low-cost reagents ($3.20/test) and an off-the-shelf Glucometer. The test was engineered around a Glucometer as it is quantitative, easy to use, and the most prevalent piece of diagnostic equipment globally, making the test highly scalable with an infrastructure that is already in place. Furthermore, many Glucometers connect to smartphones, providing an opportunity to integrate with contact tracing apps, medical providers, and electronic health records. In clinical testing, the developed assay detected SARS-CoV-2 infection in patient saliva across a range of viral loads - as benchmarked by RT-qPCR - within 1 h, with 100% sensitivity (positive percent agreement) and distinguished infected specimens from off-target antigens in uninfected controls with 100% specificity (negative percent agreement). We propose that this approach provides an inexpensive, rapid, and accurate diagnostic for distributed screening of SARS-CoV-2 infection at scale.
-
hitting the diagnostic sweet spot point of care sars cov 2 salivary antigen testing with an off the shelf Glucometer
2020Co-Authors: Naveen K Singh, Partha Ray, Aaron F Carlin, Celestine Magallanes, Sydney C Morgan, Louise C Laurent, Eliah Aronoffspencer, Drew A HallAbstract:Abstract Significant barriers to the diagnosis of latent and acute SARS-CoV-2 infection continue to hamper population-based screening efforts required to contain the COVID-19 pandemic in the absence of effective antiviral therapeutics or vaccines. We report an aptamer-based SARS-CoV-2 salivary antigen assay employing only low-cost reagents ($3.20/test) and an off-the-shelf Glucometer. The test was engineered around a Glucometer as it is quantitative, easy to use, and the most prevalent piece of diagnostic equipment globally making the test highly scalable with an infrastructure that is already in place. Furthermore, many Glucometers connect to smartphones providing an opportunity to integrate with contract tracing apps, medical providers, and electronic medical records. In clinical testing, the developed assay detected SARS-CoV-2 infection in patient saliva across a range of viral loads - as benchmarked by RT-qPCR - within one hour, with 100% sensitivity (positive percent agreement) and distinguished infected specimens from off-target antigens in uninfected controls with 100% specificity (negative percent agreement). We propose that this approach can provide an inexpensive, rapid, and accurate diagnostic for distributed screening of SARS-CoV-2 infection at scale.